RecruitingPhase 3NCT05613478

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

Studying Leukoencephalopathy with calcifications and cysts

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The First Affiliated Hospital with Nanjing Medical University
Principal Investigator
Xuehao Wang, professor
The First Affiliated Hospital with Nanjing Medical University
Intervention
Camrelizumab(drug)
Enrollment
130 enrolled
Eligibility
18 years · All sexes
Timeline
20232027

Study locations (1)

Collaborators

Jiangsu Hengrui Pharmaceutical Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05613478 on ClinicalTrials.gov

Other trials for Leukoencephalopathy with calcifications and cysts

Additional recruiting or active studies for the same condition.

See all trials for Leukoencephalopathy with calcifications and cysts

← Back to all trials